British Dragon Pharma Mastabol 200

IDENTITYCompoundDrostanolone Enanthate
EsterEnanthate
Strength200 mg/ml
FormOil Injectable
ClassDHT Derivative

PHARMACOLOGYAdministrationIntramuscular
AndrogenHigh Activity
AromatizationMinimal
17α AlkylationAbsent
ProfileLonger Ester

SAFETYHPTA EffectSuppressive
Liver RiskLow Oral Risk
Lipid RiskPossible
Androgenic RiskSignificant
MonitoringEssential

STORAGE/PACKAGEBrandBritish Dragon Pharma
Package10 ml Vial
Strength200 mg/ml
StorageLabel Specific
ProtectionLight & Heat

DOSING Common Range200–400 mg/week
Frequency1–2x Weekly
AdministrationIntramuscular Injection
Typical Period8–12 Weeks
TimingSplit Weekly Dose

USAGE PROFILEUsageBodybuilding Research
AdministrationIM Injection
Concentration200 mg/ml
Injection DaysWeekly Schedule
PeriodSeveral Weeks

RECOVERYSuppressionPossible
RecoveryVariable
PCT StatusNo Standard Protocol
MonitoringHormonal Testing
Follow-upClinician Guided

STACKING/COMPATIBILITYTestosteroneCommon Combination
Lean MassAndrogen-Based Stack
Oral AASAdded Risk
MonitoringLipids & Hematocrit
ApproachAvoid Excessive Stacking

MECHANISM OF ACTIONTargetAndrogen Receptor
ClassDHT Derived
StructureAndrostane Steroid
AromataseMinimal Conversion
EffectAndrogen Signaling

PHARMACOKINETICSEsterEnanthate
ReleaseDepot Based
MetabolismHepatic
EliminationMetabolic Clearance
Half-LifeLimited Human Data

CONTRAINDICATIONSPregnancyContraindicated
ProstateAssess Clinically
CardiovascularRisk Assessment
LipidsMonitor Closely
LiverMonitor Function

CHEMICAL PROFILEFormulaC25H40O3
Weight388.59 g/mol
CASNot Established
ClassDHT Derivative
ATCNot Assigned

ESTER COMPARISONPropionateShorter Acting
EnanthateLonger Acting
ReleaseSlower Depot
FrequencyLower Frequency
DurationExtended Exposure

COMPARISONS/ALTERNATIVESDrostanoloneDHT Derivative
TestosteroneAromatizable Androgen
MethenoloneDHT Related
OxandroloneOral DHT Derivative
SelectionContext Dependent

WHO IT'S FORClinical UseSpecific Indications
AthletesNon-Medical Use
WomenVirilization Risk
MonitoringClinician Required
PurposeMedical Assessment

BODYBUILDING USAGE

Discussed mainly for cutting phases
Often combined with testosterone
Long ester reduces frequency
Weekly dosing commonly discussed
Protocols span several weeks
HPTA suppression remains possible
Lipids require regular monitoring

WHAT IS BRITISH DRAGON?

British Dragon Pharma is the brand identified for this Mastabol 200 presentation. Brand names alone do not establish pharmaceutical authenticity, sterility, potency or manufacturing quality. Product-specific documentation and independent analytical verification are more meaningful when evaluating an injectable preparation.

WHY CHOOSE BRITISH DRAGON?

Clearly identified substance
Defined ester specification
Specified concentration
Defined injectable presentation
Batch verification recommended
Independent testing valuable

OVERVIEW

Unlike testosterone, drostanolone has a DHT-derived structure and is not expected to undergo aromatization to estradiol through the conventional testosterone pathway. However, low aromatization does not eliminate endocrine or cardiovascular risks associated with androgen exposure. PubMed literature on drostanolone provides additional pharmacological context.

BENEFITS

Androgen receptor activity
DHT-derived structure
Extended ester profile
Low aromatization tendency
Injectable depot formulation
Defined active substance
Longer release characteristics

POTENTIAL SIDE EFFECTS

Endogenous testosterone suppression
Adverse lipid changes
Blood pressure elevation
Acne and oily skin
Androgenic hair effects
Prostate-related effects
Virilization in women
Mood changes
Reduced fertility

PERFORMANCE PROFILE

Androgen Activity

85%

Anabolic Activity

75%

Lean Appearance

78%

Water Retention

15%

Aromatization

10%

DROSTANOLONE ENANTHATE FOR SALE

Drostanolone Enanthate is the active substance identified in British Dragon Pharma Mastabol 200, presented at 200 mg/ml in a 10 ml vial. Product identity, concentration, ester specification, packaging and authenticity should be verified through reliable product documentation and independent testing where appropriate.

CONCLUSION

Mastabol 200 is identified as a 200 mg/ml formulation of drostanolone enanthate, a DHT-derived androgenic-anabolic steroid. Its enanthate ester distinguishes it from the shorter propionate ester by providing a comparatively extended release profile.

For bodybuilding literature, drostanolone is commonly discussed in relation to physique-focused programs where users seek androgenic activity without direct aromatization. These performance-oriented claims should not be interpreted as established therapeutic benefits, and the absence of aromatization does not mean the compound is free of endocrine or cardiovascular effects.

There is no medically validated universal bodybuilding dosing or PCT protocol for drostanolone enanthate. Any non-medical use carries potential risks including HPTA suppression, adverse lipid changes, blood-pressure effects, androgenic adverse effects and impaired fertility. Appropriate medical assessment and laboratory monitoring are therefore important considerations.

Disclaimer

This content is provided exclusively for educational and informational purposes. It does not constitute medical advice, treatment recommendations or endorsement of non-medical anabolic steroid use. Athletic dosing and cycle protocols for drostanolone enanthate are not established clinical standards. Readers should consult qualified healthcare professionals regarding medical questions, laboratory monitoring and applicable laws in their jurisdiction.